文献速递骨软组织肉瘤与黑色素瘤

每周白蛋白结合型紫杉醇治疗儿童复发/难治性实体瘤的I期结果

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
PubMed 文献 · Eur J Cancer · 2018-06-21

虽未达到最大耐受剂量,但270 mg/m2因第1-2周期3/4级毒性被判定不可耐受,最终基于耐受性、药代动力学和抗肿瘤活性选择240 mg/m2(每周一次,每4周重复)为II期推荐剂量。58例可评估疗效患者中,1例完全缓解(2%,尤文肉瘤),4例部分缓解(7%),13例疾病稳定(22%)。

要点

  • II期推荐剂量为240 mg/m2,每周一次,每4周重复(第1、8、15天给药)。
  • 最常见3/4级不良事件为血液学毒性:中性粒细胞减少36%、白细胞减少36%、淋巴细胞减少25%。
  • 270 mg/m2因第1-2周期3/4级毒性(中性粒细胞减少5/7、皮肤毒性2/7、周围神经病变1/7)被判定不可耐受。

核心结论

  • 每周白蛋白结合型紫杉醇在儿童复发/难治性实体瘤中II期推荐剂量为240 mg/m2(每周一次,每4周重复),基于耐受性、药代动力学和抗肿瘤活性选定。
  • 虽未达到最大耐受剂量,但270 mg/m2因第1-2周期3/4级毒性被判定不可耐受。

研究设计与样本

  • 采用滚动6剂量递增设计,剂量为120、150、180、210、240或270 mg/m2,第1、8、15天给药,每4周重复,以确定最大耐受剂量和II期推荐剂量。

主要发现

  • 剂量限制性毒性为120 mg/m2时3级头晕和270 mg/m2时持续>7天的4级中性粒细胞减少。
  • 最常见3/4级不良事件为血液学毒性:中性粒细胞减少36%、白细胞减少36%、淋巴细胞减少25%。
  • 58例可评估疗效患者中,完全缓解1例(2%,尤文肉瘤),部分缓解4例(7%;横纹肌肉瘤、尤文肉瘤、伴肺转移的高级别恶性肾肿瘤、肉瘤非特指型),所有缓解均发生在≥210 mg/m2剂量。
  • 13例(22%)疾病稳定(其中5例持续≥16周,按RECIST标准)。

关键数值与推荐

  • II期推荐剂量:240 mg/m2,每周一次,每4周重复(第1、8、15天给药),接近成人转移性乳腺癌该方案推荐单药剂量的两倍。
  • 270 mg/m2因第1-2周期3/4级毒性被判定不可耐受:中性粒细胞减少5/7、皮肤毒性2/7、周围神经病变1/7。

临床怎么用

  • 儿童复发/难治性实体瘤可考虑每周白蛋白结合型紫杉醇240 mg/m2(第1、8、15天给药,每4周重复)作为II期推荐剂量。
  • 治疗期间需密切监测血液学毒性、皮肤毒性和周围神经病变。
  • II期正在入组复发/难治性神经母细胞瘤、横纹肌肉瘤和尤文肉瘤患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with recurrent/refractory solid tumours treated with nab-paclitaxel are reported. PATIENTS AND METHODS: Patients with recurrent/refractory extracranial solid tumours received nab-paclitaxel on days 1, 8 and 15 every 4 weeks at 120, 150, 180, 210, 240, or 270 mg/m2 (rolling-6 dose-escalation) to establish the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). RESULTS: Sixty-four patients were treated. Dose-limiting toxicities were grade 3 dizziness at 120 mg/m2 and grade 4 neutropenia >7 days at 270 mg/m2. The most frequent grade 3/4 adverse events were haematologic, including neutropenia (36%), leukopenia (36%) and lymphopenia (25%). Although the MTD was not reached, 270 mg/m2 was declared non-tolerable due to grade 3/4 toxicities during cycles 1-2 (neutropenia, n = 5/7; skin toxicity, n = 2/7; peripheral neuropathy, n = 1/7). Of 58 efficacy-evaluable patients, complete response occurred in one patient (2%; Ewing sarcoma) and partial responses in four patients (7%; rhabdomyosarcoma, Ewing sarcoma, renal tumour with pulmonary metastases [high-grade, malignant] and sarcoma not otherwise specified); all responses occurred at ≥210 mg/m2. Thirteen patients (22%) had stable disease (5 lasting ≥16 weeks) per RECIST. CONCLUSIONS: nab-Paclitaxel 240 mg/m2 qw3/4 (nearly double the adult recommended monotherapy dose for this schedule in metastatic breast cancer) was selected as the RP2D based on the tolerability profile, pharmacokinetics and antitumour activity. Phase II is currently enrolling patients with recurrent/refractory neuroblastoma, rhabdomyosarcoma and Ewing sarcoma. CLINICALTRIALS.GOV: NCT01962103. EUDRACT: 2013-000144-26.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Moreno L, Casanova M, Chisholm JC, et al. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. Eur J Cancer. 2018. PMID: 29936064. doi:10.1016/j.ejca.2018.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。